Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Beam Therapeutics ( (BEAM) ) has issued an announcement.
Beam Therapeutics announced advancements in its base editing portfolio with key milestones anticipated in 2025. This progress is expected to bolster its industry positioning by advancing clinical programs, which aim to deliver life-long, curative genetic medicines, potentially impacting stakeholders through enhanced therapeutic options and financial stability.
More about Beam Therapeutics
Beam Therapeutics operates in the biotechnology industry, specializing in precision genetic medicines using base editing technology. The company focuses on developing therapies for rare and common diseases, including sickle cell disease, alpha-1 antitrypsin deficiency, and glycogen storage disease, with a platform capable of rapidly programmable precision medicines.
YTD Price Performance: 6.84%
Average Trading Volume: 1,200,954
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $2.19B
For a thorough assessment of BEAM stock, go to TipRanks’ Stock Analysis page.
